Perseus-Soros Biopharmaceutical Fund
23
30M
14
5
0.39
8
- Areas of investment
Summary
The leading representative office of defined VC is situated in the New York. The company was established in North America in United States.
The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Perseus-Soros Biopharmaceutical Fund, startups are often financed by InterWest Partners, HealthCare Ventures, Frazier Healthcare Partners. The meaningful sponsors for the fund in investment in the same round are HealthCare Ventures, Montreux Equity Partners, Schroder Ventures. In the next rounds fund is usually obtained by Roche Venture Fund, L Capital Partners, HealthCare Ventures.
We can highlight the next thriving fund investment areas, such as Health Diagnostics, Biopharma. The fund has exact preference in some founders of portfolio startups. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline Auxilium Pharmaceuticals, Myogen, CeNeRx BioPharma Besides, a startup needs to be aged 4-5 years to get the investment from the fund.
The top activity for fund was in 2004. Deals in the range of 10 - 50 millions dollars are the general things for fund. Considering the real fund results, this VC is 3 percentage points less often commits exit comparing to other organizations. This Perseus-Soros Biopharmaceutical Fund works on 10 percentage points more the average amount of lead investments comparing to the other organizations. The top amount of exits for fund were in 2012. The fund is constantly included in less than 2 investment rounds annually.
Investments analytics
Analytics
- Total investments
- 23
- Lead investments
- 5
- Exits
- 8
- Follow on index
- 0.39
- Investments by industry
- Biotechnology (21)
- Health Care (12)
- Pharmaceutical (10)
- Biopharma (6)
- Medical (5) Show 5 more
- Investments by region
-
- United States (21)
- Peak activity year
- 2004
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 21
- Avg. valuation at time of investment
- 279M
- Group Appearance index
- 1.00
- Avg. company exit year
- 11
- Avg. multiplicator
- 11.94
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Ambit Biosciences | 12 May 2005 | Biotechnology, Health Care, Biopharma | Late Stage Venture | 31M | United States, California, San Diego |
| Oculex Pharmaceuticals | 22 Oct 2002 | Biotechnology, Health Care, Pharmaceutical | Early Stage Venture | 50M | United States, California, Sunnyvale |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.